Concerns about GlaxoSmithKline PLC’s diabetes drug’s links to heart attacks have been reignited after a Senate report urged the Food and Drug Administration to make changes. “People familiar with the situation say agency leaders held calls over the weekend to discuss how to address complaints from Sens. Max Baucus (D., Mont.) and Chuck Grassley (R., Iowa), who released a new report Saturday on the Glaxo drug, called Avandia. The FDA is trying to assemble a timeline of what the FDA knew of risks associated with Avandia, these people say, and plans to call a meeting of an outside advisory committee in the next few months to look at recent information on the drug, which Glaxo reported as having global sales of £771 million ($1.2 billion) in 2009. According to a two-year investigation by the Senate Finance Committee, Glaxo knew about data linking Avandia to elevated risk of cardiovascular events for several years, but played down the information and tried to suppress doctors who raised concerns. Starting in 1999, Glaxo executives complained to superiors about researchers who questioned Avandia’s safety, the report says.”
Skilled hunters adapted to the changing landscape and left tantalizing clues to who they were.
Ways to move forward when you're wrong and I'm right.
Research suggests that to maintain a healthy brain, we should tend our gut microbiome.